9201 West Broadway Avenue
Suite 650
Minneapolis, MN 55445
United States
763 416 2840
https://www.cvrx.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 200
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Kevin Hykes | President, CEO & Director | 37.06k | N/D | 1966 |
Mr. Jared Oasheim | Chief Financial Officer | 576.72k | N/D | 1984 |
Mr. Paul Verrastro | Chief Marketing & Strategy Officer | 598.97k | N/D | 1963 |
Mr. Paul Pignato | Vice President of Operations | N/D | N/D | N/D |
Ms. Jonelle R. Burnham | Vice President & General Counsel | N/D | N/D | 1971 |
Ms. Jennifer E. Englund | Senior Vice President of Global Clinical Affairs | N/D | N/D | N/D |
Dr. Philip B. Adamson M.D., M.Sc. | Chief Medical Officer | N/D | N/D | N/D |
Ms. Bonnie Handke M.B.A., R.N. | Senior Vice President of Patient Access, Reimbursement, & Healthcare Economics | N/D | N/D | N/D |
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
La calificación ISS Governance QuickScore de CVRx, Inc. a partir del 1 de junio de 2024 es 10. Las puntuaciones principales son Auditoría: 7; Junta: 9; Derechos del accionista: 8; Compensación: 10.